M. A. Dimopoulos Et Al. , "Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial," LANCET ONCOLOGY , vol.22, no.6, pp.801-812, 2021
Dimopoulos, M. A. Et Al. 2021. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. LANCET ONCOLOGY , vol.22, no.6 , 801-812.
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., BEKSAÇ, M., Katodritou, E., ... Moreau, P.(2021). Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. LANCET ONCOLOGY , vol.22, no.6, 801-812.
Dimopoulos, ALİ Et Al. "Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial," LANCET ONCOLOGY , vol.22, no.6, 801-812, 2021
Dimopoulos, ALİ Et Al. "Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial." LANCET ONCOLOGY , vol.22, no.6, pp.801-812, 2021
Dimopoulos, M. A. Et Al. (2021) . "Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial." LANCET ONCOLOGY , vol.22, no.6, pp.801-812.
@article{article, author={ALİ ÜNAL Et Al. }, title={Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial}, journal={LANCET ONCOLOGY}, year=2021, pages={801-812} }